04 · Five things to know

Five things to know

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 5 min read

Bookmarks need a Mind Club sign-in. How sign-in works

Five things to know across your briefs

Pan-RAS drugs report pancreatic cancer responses, and Actinogen’s Alzheimer’s trial misses.

01

Must read

Erasca’s pan-RAS pill ERAS-0015 drew confirmed responses in 44% of 25 previously treated pancreatic cancer patients

What happened

Erasca reported updated Phase 1 data from AURORAS-1 on 11.20 for ERAS-0015, an oral drug it calls a pan-RAS molecular glue that also hits normal, unmutated RAS. At 32 mg once daily, 44% of 25 previously treated pancreatic cancer patients with KRAS G12X mutations had a confirmed response (95% CI about 24 to 65%, our calculation). In the 13 with G12D or G12V, it was 69% (about 39 to 91%). In lung cancer after immunotherapy and platinum it was 60% (n=5), and in biliary tract cancer 75% (n=4). Across 122 patients on 16 to 32 mg, there were no dose-limiting toxicities. At 32 mg, 13.0% had doses interrupted, 16.7% had doses reduced and none stopped. A grade 5 pneumonitis was first disclosed in April 2026. Erasca plans a first-line pancreatic Phase 3 to start in the first half of 2027. Claim

Why it matters

These are small, single-arm groups with no control, so they cannot show the drug beats other treatment, and a response rate is not survival. They add a second pan-RAS drug to a field where daraxonrasib is already approved. Analysis

What we’re watching

Durability of the responses, a full grade 3 or higher adverse event count, and the Phase 3 designs.

CLAIM CHECK

Partial NCT06983743 registers dose-limiting toxicities, maximum tolerated dose, recommended dose, adverse events and pharmacokinetics as primaries; response rate, the headline, is a secondary.

Erasca (11.20) (opens another website in a new tab) Co; NCT06983743 (opens another website in a new tab) Reg

02

Must read

Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer

What happened

In a late-breaker at ENA 2026, Revolution Medicines reported updated Phase 1/2 data for Rasonque (daraxonrasib), 200 mg, with gemcitabine and nab-paclitaxel as first-line treatment for metastatic pancreatic cancer. In 61 patients followed for a median of 18.3 months, 60.7% had a confirmed response (95% CI 47.3 to 72.9). Complete responses were 8.2%. Median progression-free survival was 12.8 months and the 12-month overall survival rate 76.6%. The company called the safety consistent with the known profiles and gave no grade 3 or higher rates in its release. The randomized Phase 3 RASolute 303 is ongoing. Claim

Why it matters

FDA approved daraxonrasib on 08.26.2026 for metastatic pancreatic cancer after prior systemic therapy, or when multiagent therapy is not an option. These first-line numbers come from one arm with no comparator, so they cannot be set against chemotherapy alone. Analysis

What we’re watching

RASolute 303’s readout and the grade 3 or higher toxicity of the combination.

CLAIM CHECK

Partial The release gives no registry number. The matching study we found, NCT06445062, a platform trial, registers adverse events and dose-limiting toxicities as primaries for this combination; response and survival are secondaries.

Revolution Medicines release on GlobeNewswire, read through Investing News (11.19) (opens another website in a new tab) Co; NCT06445062 (opens another website in a new tab) Reg

03

Must read

Actinogen’s pivotal Xanamem trial in Alzheimer’s disease missed its primary endpoint

What happened

Actinogen said on 11.19 that XanaMIA, a randomized, double-blind, placebo-controlled Phase 2b/3 trial of Xanamem (emestedastat), an oral 11β-HSD1 inhibitor, in 247 people with mild to moderate Alzheimer’s disease and raised pTau181, missed its primary endpoint. The mean benefit on CDR-SB at week 36 was 0.10 points versus placebo (p = 0.65), which the company calls “numerically, but not statistically superior.” In a prespecified subgroup above the median age of 75, 40% versus 22% showed no progression on CDR-SB (p = 0.02), while the mean slowing of 0.39 points was not significant (p = 0.22). The company reports no drug-related serious adverse events and plans talks with FDA and partners on a path in older patients. Claim

Why it matters

A subgroup result after a missed primary can point to the next trial but cannot carry this one. Analysis

What we’re watching

What FDA says about the older-patient path, and the open-label extension results the company plans to present at a future scientific meeting.

CLAIM CHECK

Match NCT06125951 registers CDR-SB change at 36 weeks as its efficacy primary, with adverse events as a second primary, and 247 enrolled; the release reports that measure. The age subgroup is not a registered primary.

Actinogen, via BioSpace (11.19) (opens another website in a new tab) Co; Biotech Dispatch (11.19) (opens another website in a new tab) Press; NCT06125951 (opens another website in a new tab) Reg

04

Know it

Regeneron’s Livsayis, an RNAi drug discovered by Alnylam, was approved for generalized myasthenia gravis

What happened

Alnylam said on 11.19 that FDA approved Livsayis (cemdisiran), from its collaborator Regeneron, for adults with generalized myasthenia gravis who test positive for antibodies to the acetylcholine receptor. It silences C5, a complement protein, and is given under the skin four times a year. Alnylam calls it the first RNAi therapy for the disease and the seventh approved drug discovered by Alnylam, and it receives a $25M milestone and royalties of up to 15%. FDA’s novel approvals list dates the approval itself to 11.18. Claim

C5 blockade is already used in this disease; dosing four times a year is the difference the companies stress. We did not read the label. Analysis

Alnylam release on Business Wire, read through Yahoo Finance (11.19) (opens another website in a new tab) Co; PharmExec (opens another website in a new tab) Press

05

Know it

AbbVie took an option on AND-gated bispecifics from DISCO; Bloomberg reports Sanofi is weighing a bid for Insmed

What happened

AbbVie and DISCO Pharmaceuticals agreed on 11.19 to a research collaboration with an option to license AND-gated bispecific antibodies for solid tumors, which aim to act only on cells carrying two antigens. DISCO gets $40M upfront and is eligible for up to $2.5B in option, development and other milestones, plus royalties; targets were not disclosed. AbbVie Ventures is an existing investor in DISCO, a company in Cologne, Germany, which closed a €36M seed round in December 2025. Separately, Bloomberg reported, citing unnamed people, that Sanofi is weighing a takeover bid for Insmed. No price was reported, Insmed declined to comment, and no deal has been announced. Claim

The DISCO upfront is small next to its milestones, so most of the headline value depends on future options. A reported interest in a deal is not a deal. Analysis

BioSpace (11.19) (opens another website in a new tab); Bloomberg report as relayed by Pharmaceutical Technology (11.20) (opens another website in a new tab) Press; Sofinnova Partners (12.11.2025) (opens another website in a new tab) Co

BRIGHT SPOTIn NEJM, the PARADIGM4TB platform trial tested new four-drug, 16-week tuberculosis regimens in 401 people. A regimen built on the DprE1 inhibitor BTZ-043 cleared culture faster than standard treatment, by 20.5% on the trial’s measure (posterior probability of superiority 0.99). Grade 3 or higher adverse events were 28% versus 24%, and one regimen showed a signal of excess liver toxicity and was not taken forward. Verified Peer NEJM (11.19) (opens another website in a new tab); Reg NCT06114628 (opens another website in a new tab)